(Q37792839)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Jens Juul Holst

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

M A Nauck

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

I Vardarli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

J J Meier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

1 reference

25 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

54

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

10-18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20871975%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00125-010-1896-4

14 February 2020

exact match

0 references

cites work

Neural regulation of glucagon-like peptide-1 secretion in pigs

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-010-1896-4

Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00125-010-1896-4

Carbohydrate Digestion and Absorption

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion

1 reference

12 December 2020

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

1 reference

12 December 2020

First-phase insulin secretion restoration and differential response to glucose load depending on the route of administration in type 2 diabetic subjects after bariatric surgery.

1 reference

12 December 2020

Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*

1 reference

12 December 2020

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

1 reference

12 December 2020

Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans

1 reference

12 December 2020

Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men.

1 reference

12 December 2020

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

1 reference

12 December 2020

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1

1 reference

12 December 2020

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

1 reference

12 December 2020

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1 reference

12 December 2020

Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences

1 reference

12 December 2020

Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance

1 reference

12 December 2020

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

1 reference

12 December 2020

Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes.

1 reference

12 December 2020

Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients

1 reference

12 December 2020

Gastric emptying and release of incretin hormones after glucose ingestion in humans

1 reference

12 December 2020

Incretin hormones--an update.

1 reference

12 December 2020

Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus

1 reference

12 December 2020

Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man

1 reference

12 December 2020

The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics

1 reference

12 December 2020

Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients

1 reference

12 December 2020

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

1 reference

12 December 2020

Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut

1 reference

12 December 2020

Exenatide pharmacokinetics in healthy Chinese subjects

1 reference

12 December 2020

Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

12 December 2020

Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects

1 reference

12 December 2020

Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

1 reference

12 December 2020

Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop

1 reference

12 December 2020

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

12 December 2020

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

1 reference

12 December 2020

Attenuated GLP-1 secretion in obesity: cause or consequence?

1 reference

12 December 2020

Colocalization of GLP-1 and GIP in human and porcine intestine

1 reference

12 December 2020

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

12 December 2020

Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors

1 reference

12 December 2020

Gut hormones and diabetes mellitus

1 reference

12 December 2020

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

1 reference

12 December 2020

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

1 reference

12 December 2020

Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes.

1 reference

12 December 2020

Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve

1 reference

12 December 2020

Enhanced secretion of glucagon-like peptide 1 by biguanide compounds

1 reference

12 December 2020

Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

12 December 2020

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

1 reference

12 December 2020

Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion

1 reference

12 December 2020

The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia

1 reference

12 December 2020

GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell

1 reference

12 December 2020

Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120

1 reference

12 December 2020

Reduced Incretin Effect in Type 2 Diabetes

1 reference

12 December 2020

Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion

1 reference

12 December 2020

Incretins and their analogues as new antidiabetic drugs.

1 reference

12 December 2020

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

1 reference

12 December 2020

Glucagon-like peptide-1 secretion is influenced by perfusate glucose concentration and by a feedback mechanism involving somatostatin in isolated perfused porcine ileum

1 reference

12 December 2020

The potential role of glucagon-like peptide 1 in diabetes.

1 reference

12 December 2020

Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycemia after total gastrectomy

1 reference

12 December 2020

Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells

1 reference

12 December 2020

Hypersecretion of truncated glucagon-like peptide-1 and gastric inhibitory polypeptide in obese patients.

1 reference

12 December 2020

Physiological augmentation of amino acid-induced insulin secretion by GIP and GLP-I but not by CCK-8.

1 reference

12 December 2020